Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate.

Pharmaceutics·2026

Same author

Drug-controlled CAR T cells through the regulation of cell-cell interactions.

Nature chemical biology·2026

Same author

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

International journal of molecular sciences·2025

Same author

Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion.

Cells·2025

Same author

CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges.

Nature reviews. Gastroenterology & hepatology·2025

Same author

Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release.

Cancers·2024

Search research articles

Related Experiment Video

Updated: Jun 20, 2025

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

Transforming the Dark into Light: A Siglec-9 Switch.

Hinrich Abken¹

¹Division of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany.

Cancer Immunology Research

|July 22, 2024

Summary

Tumor cells use increased sialylation to suppress immune responses. Researchers developed a Siglec-9 "switch" receptor to convert this suppression into immune activation, enhancing T-cell therapy for cancer.

Area of Science:

Immunology
Cancer Biology
Glycobiology

Background:

Tumor-associated immune repression limits T-cell therapy efficacy.
Aberrant glycosylation is a key mechanism of immune evasion in cancer.

Purpose of the Study:

To investigate the role of aberrant glycosylation in tumor-induced immune suppression.
To develop a novel strategy to overcome immune checkpoints in cancer therapy.

Main Methods:

Analysis of IFNγ-induced hyper-sialylation in cancer cells.
Development and testing of a chimeric Siglec-9 "switch" receptor.
Evaluation of T-cell responses in tumor tissue.

Main Results:

IFNγ induces cancer cell hyper-sialylation, creating an inhibitory checkpoint via Siglec-9.

More Related Videos

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Related Experiment Videos

Last Updated: Jun 20, 2025

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo

Published on: August 4, 2021

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

The Siglec-9 switch receptor effectively converts suppressive signals into stimulatory ones.

Restored T-cell responses were observed in tumor tissues.

Conclusions:

Targeting the Siglec-9/sialylation axis offers a promising strategy to enhance cancer immunotherapy.
The Siglec-9 switch receptor has significant implications for adoptive cell therapy.
Overcoming tumor immune evasion through engineered immune receptors is feasible.